BIOLOGIC/DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD)
Ilumya is approved by the Food and Drug Administration (FDA) to treat adults with moderate to severe plaque psoriasis in cases where systemic therapy or phototherapy are warranted. Ilumya is also referred to by its drug name, Tildrakizumab-asmn.
Ilumya is an immunomodulator, or in other words, a drug that modulates the immune system. Specifically, Ilumya is considered a biologic disease-modifying antirheumatic drug (DMARD). Ilumya is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Ilumya is believed to work by inhibiting interleukin (IL)-23, a chemical messenger involved in autoimmune attacks. Ilumya prevents IL-23 from signaling the immune system to attack the tissues.
How do I take it?
Prescribing information states that Ilumya is administered as a subcutaneous injection every 12 weeks after initial loading doses.
Ilumya comes in a prefilled, single-dose syringe.
The FDA-approved label for Ilumya lists common side effects including upper respiratory infections, diarrhea, and injection site reactions.
Rare but serious side effects listed for Ilumya include hypersensitivity reactions and increased risk for severe infections.
For more details about this treatment, visit:
Highlights of prescribing information – Sun Pharma